# BIODESIX, INC. (BDSX) · Edgar & Edgarette company card

> Biodesix (BDSX) grew revenue 24.1% in FY2025 to $88 million, operating margin -31.5% against a -12.4% median for medical laboratories, equity -2.8% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1439725 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/BDSX) · [JSON](https://www.pops4.com/boards/company/BDSX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $88M |
| Revenue growth, 1 year | 24.1% |
| Revenue growth per year | 12.9% |
| Operating margin | -31.5% (prior year -48.4%) |
| Net margin | -39.8% |
| Operating cash flow | −$23M |
| Capital spending | $259,000 |
| Free cash flow | −$24M |
| Cash | $19M |
| Long-term debt | $50M |
| Total assets | $87M |
| Total equity | −$2M |
| Equity ÷ assets | -2.8% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -19.59 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative; operating loss: a margin of -31.5% in FY2025; revenue is hard to predict: its 80% range is ±53%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $88.5M (FY2025), total debt $50.0M. Experience: revenue up 24.1% on the year, up 12.9% a year over 4 years; operating margin -31.5%, up from -48.4%. Soundness: equity -2.8% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $60.5M and $196.1M next year (method v4.1: its own 6-year record of growth weighed at 63% against $50M–100M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $63.2M to $188.2M. A statistical range, not company guidance. Against peers (17 filers, $50M+ revenue, services-medical laboratories): operating margin -31.5% against a -12.4% median; growth 24.1% against 13.8%.

Range logged 2026-11-01, receipt 87cebf01b18a7a7e, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-11-05 ([filing](https://www.sec.gov/Archives/edgar/data/1439725/000119312526449792/0001193125-26-449792-index.htm))

## Recent filings

- 8-K · filed 2026-11-05 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1439725/000119312526449792/0001193125-26-449792-index.htm)
- 10-Q · filed 2026-11-05 · [filing](https://www.sec.gov/Archives/edgar/data/1439725/000119312526449763/0001193125-26-449763-index.htm)
- 8-K · filed 2026-11-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1439725/000119312526449738/0001193125-26-449738-index.htm)
- 10-Q · filed 2026-08-05 · [filing](https://www.sec.gov/Archives/edgar/data/1439725/000119312526335036/0001193125-26-335036-index.htm)
- 8-K · filed 2026-08-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1439725/000119312526335010/0001193125-26-335010-index.htm)
- 8-K · filed 2026-05-20 · 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1439725/000119312526232631/0001193125-26-232631-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001439725.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1439725

## Cite

POPS4, Edgar & Edgarette: BIODESIX, INC. (BDSX) company card, from the company's own SEC filings, accessed 2026-11-06, https://www.pops4.com/boards/company/BDSX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.